Better Buy: Eli Lilly vs. Novo Nordisk

Eli Lilly is framed as the better buy versus Novo Nordisk after Q2 results, with Lilly’s GLP-1 franchise showing stronger momentum. In weight-loss, Zepbound generated $4.9B revenue (+46% YoY) while Novo’s Wegovy delivered ~DKK 19.4B (about $3B), up only ~1% YoY. Despite valuation differences (Lilly cited at 32.7x vs Novo at 13.8x forward earnings), the article argues Lilly’s faster revenue/earnings growth and broader pipeline make it the superior option.

Analysis

This is fundamentally a relative-share and multiple-compounding trade, not just a quarterly print. The company with stronger efficacy and a broader pipeline should keep winning formulary pull-through, which matters because obesity drugs are becoming a platform business: better persistence, better refill economics, and more leverage over payer negotiations. That creates a flywheel for the leader, while the laggard risks becoming a low-growth cash generator with a value trap multiple.

The second-order issue is capacity and mix. If the winner keeps taking share, suppliers, fill-finish partners, and downstream pharmacy channels will see a steadier volume ramp, while the loser’s manufacturing base can become underutilized and its rebate burden rises to defend access. Over the next 1-3 quarters, watch script-share trends and any guidance changes more than headline sales; over 6-18 months, the real swing factor is whether oral or next-gen data can reset prescriber expectations.

Contrarianly, the market may already be over-owning the obvious winner and underestimating how much of its outperformance is now embedded in the stock. The better asymmetry may actually be in the disfavored name if sentiment is washed out and pipeline readouts surprise positively. But absent a clear clinical or commercial inflection, the burden of proof stays on the laggard, and the more likely path is multiple compression on any evidence that share losses are structural rather than temporary.

Key Decisions for Investors

• Long LLY / short NVO as a beta-adjusted pair for the next 1-3 months; thesis is continuing share divergence and multiple divergence. Falsify if NVO shows two straight quarters of accelerating obesity revenue or LLY guides down on supply constraints.
• If chasing exposure to the winner, prefer buying LLY on a pullback rather than after strength; use a 3-6 month call spread to limit valuation risk. The trade works if LLY keeps compounding growth while the market remains willing to pay up for durability.
• Avoid initiating fresh outright longs in NVO until there is evidence of regained share or a meaningful pipeline catalyst; otherwise it is a value trap candidate despite the lower forward multiple.